Actively Recruiting
Study of Personalized mRNA Vaccine iNeo-Vac-R01 with Standard Adjuvant Therapy in Adults With Surgically Removed Digestive System Cancers
Led by Sir Run Run Shaw Hospital · Updated on 2023-09-11
20
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, feasibility, and effectiveness of a personalized mRNA vaccine called iNeo-Vac-R01 combined with standard adjuvant therapy in people who have had surgery to remove digestive system cancers. This Phase 1 clinical trial focuses on subjects with surgically resected digestive system neoplasms, including cancers such as cholangiocarcinoma, pancreatic cancer, hepatocellular carcinoma, gastric cancer, and colorectal carcinoma. Participants will first receive at least four cycles of standard adjuvant therapy following surgery, based on clinical guidelines. Then, they will receive the personalized mRNA vaccine iNeo-Vac-R01 through intramuscular injections on the first day of each 21-day cycle for up to nine cycles. The vaccine dose is determined during an earlier dose escalation phase of the study. Throughout the study, participants will undergo assessments including monitoring for adverse events up to 21 days after the last vaccine dose. Researchers will also evaluate overall survival, recurrence-free survival, immune responses involving T cells and cytokines, and the absence of disease recurrence at 12 and 24 months after the first vaccine dose. The total follow-up period for key outcomes extends up to three years after starting the vaccine treatment.
CONDITIONS
Brief Title
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Research Team
X
Xiujun Cai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here